Agenus Inc. has expanded its global Medical Affairs infrastructure to support growing physician interest in authorized access to its investigational immunotherapy combination, botensilimab plus balstilimab (BOT+BAL). The expansion aims to facilitate scientific exchange, coordinate access requests, support pharmacovigilance, and enable structured collection of real-world safety and outcomes data. This scale-up also supports France's multi-tumor AAC access framework and the company's expanding paid named-patient programs in select countries.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260121295490) on January 21, 2026, and is solely responsible for the information contained therein.